Celoxica implements performance acceleration for US life-sciences company

Celoxica Holdings - a leading provider of FPGA based High Performance Computing solutions, announces the successful implementation of data analysis acceleration in the life sciences environment. Genetic analysis is a fundamental process in modern drug discovery and development but places great demands on data processing. Working with a respected US Life Sciences company, Celoxica was able to accelerate the client's gene sequencing algorithm by a factor of 20, significantly reducing this "bottleneck". The application of Celoxica's technology could have major benefits in the speed and cost of drug development. This follows the announcement last month of two other successful proof of concept projects in the financial services market. Lee Staines, Chief Executive of Celoxica commented, "We are delighted to announce the completion of another successful implementation within one of our key industry verticals. The ever increasing demand for higher performance coupled with a need for a reduction in power consumption is driving momentum in our market. We are seeing an increased level of awareness of our services within the financial services, life-sciences and oil and gas industries and believe the potential for our products to be significant."